ProQR Receives up to $5 Million in Partnership with EBRP and EBMRF to Develop QR-313 for DEB5/21/2018
EB Research Partnership and EBMRF partnered to fund up to $5 million for ProQR's Phase 1/2 human clinical trial of QR-313, a potential therapy for Dystrophic Epidermolysis Bullosa (DEB). QR-313 addresses mutations in exon 73 of the Collagen VII gene through exon skipping, causing the production of functional protein.
Comments are closed.
|
|
|
|
|
|
|
|
